Literature DB >> 35298351

LncRNA RP3-326I13.1 promotes cisplatin resistance in lung adenocarcinoma by binding to HSP90B and upregulating MMP13.

Huixin Zhou1, Xiaolu Huang1, Wenjing Shi1, Shihao Xu2, Jie Chen3, Kate Huang4, Yumin Wang1.   

Abstract

Cisplatin (DDP) resistance has become the major obstacle in the therapy of malignant tumors, including lung adenocarcinoma (LAD). Long non-coding RNAs (lncRNAs) were confirmed to be related to DDP-resistance. Studies have shown that RP3-326I13.1 (also known as PINCR) could promote the progression of colorectal cancer, and RP3-326I13.1 knockdown could induce hypersensitivity to chemotherapy drugs. While the function of RP3-326I13.1 in LAD is unclear, therefore, this study aimed to research the biological function and related molecular mechanisms of RP3-326I13.1 in DDP-resistance of LAD. QPCR analysis found that RP3-326I13.1 was highly expressed in A549/DDP cells and LAD tissues. Cytological assays found that RP3-326I13.1 pro-moted the proliferation, migration, invasion, and DDP-resistance of LAD cell lines. Moreover, knock-down of RP3-326I13.1 could induce G1 phase arrest. Nude mouse xenograft assay confirmed that RP3-326I13.1 could promote tumor growth and DDP-resistance in vivo. Mechanically, RNA pull-down and mass spectrometry analysis indicated that heat shock protein HSP 90-beta (HSP90B) could be combined with RP3-326I13.1. HSP90B knockdown inhibited the effect of RP3-326I13.1 on proliferation, invasion, and promoted LAD cell lines apoptosis. Transcriptome sequencing analysis found that MMP13 was the downstream mRNA of RP3-326I13.1. In conclusion, RP3-326I13.1 could promote DDP-resistance of LAD by binding to HSP90B and upregulating human matrix metalloproteinase-13 (MMP-13) and may serve as a therapeutic target, as well as a biomarker for predicting DDP-resistance in LAD.Abbreviations:DDP: Cisplatin; LAD: Lung adenocarcinoma; LncRNAs: Long non-coding RNAs; qPCR: real-time fluorescent quantitative PCR; HSP90B: Heat shock protein HSP 90-beta; RPMI: Roswell Park Memorial Institute; FBS: Fetal bovine serum; CT: computed tomography; MRI: magnetic resonance imaging; RECIST: Response evaluation criteria in solid tumors; NC: Negative control; OE: overexpression; shRNA: short hairpin RNA; siRNA: small interfering RNA; CCK-8: Cell Counting Kit-8; IC50: The half maximal inhibitory concentration; PBS: Phosphate buffer saline; PI: propidium iodide; SDS-PAGE: sodiumdodecylsulfate-polyacrylamide gel electrophoresis; ceRNA: Competing endogenous RNA; HE: hematoxylin-eosin; ns: no significance.

Entities:  

Keywords:  Lung adenocarcinoma; RP3-326I13.1; cisplatin resistance

Mesh:

Substances:

Year:  2022        PMID: 35298351      PMCID: PMC9345617          DOI: 10.1080/15384101.2022.2051971

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   5.173


  38 in total

Review 1.  The HSP90 chaperone machinery.

Authors:  Florian H Schopf; Maximilian M Biebl; Johannes Buchner
Journal:  Nat Rev Mol Cell Biol       Date:  2017-04-21       Impact factor: 94.444

Review 2.  Structure, function and regulation of the hsp90 machinery.

Authors:  Jing Li; Johannes Buchner
Journal:  Biomed J       Date:  2013 May-Jun       Impact factor: 4.910

3.  Heat shock protein 90 promotes epithelial to mesenchymal transition, invasion, and migration in colorectal cancer.

Authors:  Ganji Purnachandra Nagaraju; Tua-Elisabeth Long; Wungki Park; Jerome C Landry; LaTonia Taliaferro-Smith; Alton B Farris; Roberto Diaz; Bassel F El-Rayes
Journal:  Mol Carcinog       Date:  2014-05-27       Impact factor: 4.784

Review 4.  Heat Shock Proteins and Cancer.

Authors:  Jianming Wu; Tuoen Liu; Zechary Rios; Qibing Mei; Xiukun Lin; Shousong Cao
Journal:  Trends Pharmacol Sci       Date:  2016-12-22       Impact factor: 14.819

5.  Detection of RNA-DNA binding sites in long noncoding RNAs.

Authors:  Chao-Chung Kuo; Sonja Hänzelmann; Nevcin Sentürk Cetin; Stefan Frank; Barna Zajzon; Jens-Peter Derks; Vijay Suresh Akhade; Gaurav Ahuja; Chandrasekhar Kanduri; Ingrid Grummt; Leo Kurian; Ivan G Costa
Journal:  Nucleic Acids Res       Date:  2019-04-08       Impact factor: 16.971

6.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

Authors:  Joan H Schiller; David Harrington; Chandra P Belani; Corey Langer; Alan Sandler; James Krook; Junming Zhu; David H Johnson
Journal:  N Engl J Med       Date:  2002-01-10       Impact factor: 91.245

7.  A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression.

Authors:  Kevin C Wang; Yul W Yang; Bo Liu; Amartya Sanyal; Ryan Corces-Zimmerman; Yong Chen; Bryan R Lajoie; Angeline Protacio; Ryan A Flynn; Rajnish A Gupta; Joanna Wysocka; Ming Lei; Job Dekker; Jill A Helms; Howard Y Chang
Journal:  Nature       Date:  2011-03-20       Impact factor: 49.962

8.  Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data.

Authors:  R Arriagada; A Auperin; S Burdett; J P Higgins; D H Johnson; T Le Chevalier; C Le Pechoux; M K B Parmar; J P Pignon; R L Souhami; R J Stephens; L A Stewart; J F Tierney; H Tribodet; J van Meerbeeck
Journal:  Lancet       Date:  2010-03-24       Impact factor: 79.321

Review 9.  Translational remodeling by RNA-binding proteins and noncoding RNAs.

Authors:  J J David Ho; Jeffrey H S Man; Jonathan H Schatz; Philip A Marsden
Journal:  Wiley Interdiscip Rev RNA       Date:  2021-03-10       Impact factor: 9.957

10.  Acetyl-11-keto-β-boswellic acid enhances the cisplatin sensitivity of non-small cell lung cancer cells through cell cycle arrest, apoptosis induction, and autophagy suppression via p21-dependent signaling pathway.

Authors:  Minghe Lv; Xibing Zhuang; Qi Zhang; Yunfeng Cheng; Duojiao Wu; Xiangdong Wang; Tiankui Qiao
Journal:  Cell Biol Toxicol       Date:  2020-06-20       Impact factor: 6.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.